# Xenon Pharmaceuticals Inc. (XENE)

> Healthcare · CA · Reports in USD

Fundamental indicators from Sponda, adjusted for inflation.

[HTML version](https://sponda.capital/en/XENE/fundamentals)

## Annual figures

| Year | Revenue (M) | Net Inc. (M) | FCF (M) | Debt (M) | Equity (M) |
| --- | --- | --- | --- | --- | --- |
| 2026 | $ 0 | $ -213.04M | $ -184.70M | $ 6.42M | $ 1.24B |
| 2025 | $ 7.68M | $ -354.18M | $ -286.61M | $ 7.94M | $ 581.76M |
| 2024 | $ 0 | $ -246.30M | $ -195.49M | $ 9.02M | $ 754.90M |
| 2023 | $ 0 | $ -197.21M | $ -163.21M | $ 10.90M | $ 927.92M |
| 2022 | $ 10.54M | $ -140.05M | $ -113.19M | $ 10.44M | $ 721.50M |
| 2021 | $ 21.92M | $ -93.76M | $ -85.05M | $ 8.26M | $ 550.03M |
| 2020 | $ 40.98M | $ -36.74M | $ -65.30M | $ 3.32M | $ 171.36M |
| 2019 | $ 8.81M | $ -53.69M | $ -7.58M | $ 16.45M | $ 91.98M |
| 2018 | $ 7.92M | $ -45.56M | $ -46.53M | $ 15.01M | $ 103.30M |
| 2017 | $ 419.0K | $ -41.36M | $ -39.12M | $ 6.80M | $ 35.93M |
| 2016 | $ 2.48M | $ -31.64M | $ -27.30M | $ 0 | $ 63.90M |
| 2015 | $ 21.87M | $ -15.19M | $ -26.19M | $ 0 | $ 61.03M |
| 2014 | $ 40.09M | $ 18.39M | $ -1.78M | $ 0 | $ 72.78M |
| 2013 | $ 38.91M | $ 12.65M | $ -4.95M | $ 0 | $ 24.12M |
| 2012 | $ 8.80M | $ -4.11M | $ 56.30M | $ 0 | $ 12.62M |

Columns not available in this view: annualPriceMultiples, dividends. They require live market data and are shown on the HTML page instead.

## Leverage and liquidity

| Indicator | Value |
| --- | --- |
| Gross Debt / Eq | 0.01 |
| Liabilities / Eq | 0.04 |
| Current Ratio | 21.02 |

## Other views

- [Metrics](https://sponda.capital/en/XENE.md)
- [Charts](https://sponda.capital/en/XENE/charts.md)
- [Compare](https://sponda.capital/en/XENE/compare.md)
- [Indicator definitions](https://sponda.capital/en/screener.md)

Data as of 2026-08-29.